Pfizer (PFE) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · United States · ISIN US7170811035
Pfizer financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 62.58 bn USD |
| Gross profit | 46.51 bn USD |
| EBIT | 9.61 bn USD |
| Net income | 7.77 bn USD |
| Diluted EPS – continuing operations | 1.36 USD |
Full history since 1985, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
More stocks
- Novo Nordisk A/S (NVO)
- Schneider Electric SE (SU.PA)
- T-Mobile US (TMUS)
- Airbus SE (AIR.PA)
- Charles Schwab Corporation (SCHW)
- Petroleo Brasileiro Petrobras SA ADR (PBR)
- SOUTHERN COPPER CORP/ (SCCO)
- Iberdrola SA (IBE.MC)
- Welltower (WELL)
- DBS Group Holdings Ltd (D05.SI)
- Seagate Technology (STX)
- NextEra Energy (NEE)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.